RP1 (vusolimogene odeparepvec) + nivolumab
Advanced Melanoma
Key Facts
Indication
Advanced Melanoma
Phase
Phase 3
Status
PDUFA date July 22, 2025; Confirmatory trial enrolling
Company
About Replimune
Founded in 2015, Replimune is at the forefront of developing next-generation oncolytic immunotherapies with the mission to revolutionize cancer treatment. Its lead candidate, RP1 (vusolimogene odeparepvec), has a PDUFA date of July 22, 2025, for advanced melanoma and is being studied across multiple skin cancers. The company's wholly-owned RPx platform and in-house manufacturing capability position it to develop a broad portfolio of treatments aimed at overcoming resistance to current immunotherapies.
View full company profileTherapeutic Areas
Other Advanced Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| IO102-IO103 + pembrolizumab | IO Biotech | Phase 1/2 |